Tagged as: Trump

HHS Seeks Public Comments on Trump Administration's Plan to Lower Drug Prices

Last week the Department of Health and Human Services (HHS) issued a request for comments on the Trump administration’s plan to lower drug prices.  The HHS blueprint to lower drug prices includes improving competition by promoting innovation and competition for biologics.  According to HHS, “FDA will issue new policies to improve availability, competitiveness, and adoption of…

Read More

Will Trump's Election Impact the BPCIA?

The election last night of Donald Trump as the next President of the United States may have far-reaching consequences on numerous legal and policy issues, including immigration, international trade, and health care. Although we are not aware of President-elect Trump ever directly mentioning biosimilars on the campaign trail, it is…

Read More